RxDoctor Payments DataLook up a doctor →

Deepa Jagadeesh, MD

Internal Medicine · Worcester, MANPI 1720131766

Payments from drug & device makers

$5,560,183in general payments, 2019–2025

Across 242 payments — averaging $22,976 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Seagen Inc.$3.3M
  • Regeneron$870K
  • AstraZeneca$560K
  • Eli Lilly$468K
  • Pfizer$319K
  • Verastem, Inc.$13K
  • plus $23K from 11 others
$15,407in research payments, 2019–2025

Across 42 payments — averaging $366.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$14K
  • Pfizer$1K

What the payments were for

  • Consulting fees$34,10172%
  • Speaking & faculty fees$6,91515%
  • Travel & lodging$3,2607%
  • Food & beverage$2,9146%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,560,183 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$52,924
Medicare patients
178
Services billed
627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JaypircaPirtobrutinib18$398,224
BrukinsaZanubrutinib20$263,177
CalquenceAcalabrutinib Maleate24$260,063
Ondansetron Hcl27$1,390
Acyclovir85$1,182
Gabapentin30$654
MethotrexateMethotrexate Sodium20$382
Prochlorperazine Maleate21$261
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim48$228
Prednisone70$226
Mirtazapine13$83

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCJaypirca$24$398,22418 claims
Beigene USA, Inc.Brukinsa$139$263,17720 claims
AstraZenecaCalquence$559,795$260,06324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →